NovoCure (NVCR) Receivables - Other (2022 - 2026)

NovoCure's Receivables - Other history runs 5 years deep, the most recent figure standing at $8.2 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 25.64% year-over-year to $8.2 million; the TTM figure through Mar 2026 stood at $8.2 million (up 25.64% YoY), while the FY2025 annual figure was $7.8 million, up 36.02% from the prior year.
• Receivables - Other came in at $8.2 million for Q1 2026 at NovoCure, up from $7.8 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $8.2 million in Q1 2026 to a low of $2.2 million in Q4 2022.
• A 5-year average of $5.8 million and a median of $5.7 million in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other jumped 93.93% in 2023 and increased 25.64% in 2026, its largest moves.
• NovoCure's Receivables - Other stood at $2.2 million in 2022, then soared by 93.93% to $4.3 million in 2023, then soared by 34.67% to $5.7 million in 2024, then surged by 36.02% to $7.8 million in 2025, then climbed by 5.89% to $8.2 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $8.2 million, $7.8 million, and $7.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison